For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14 in JAMA Ophthalmology.

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes 1. In this cohort of ...

The researchers focused on a protein called hypoxia-inducible factor (HIF), which has been linked before to diabetic retinopathy and other eye diseases. In this new work, they discovered that during ...

British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...

Macular edema (ME), a leading cause of central vision loss, is often treated with anti-vascular endothelial growth factor ...

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...